From bugs to drugs: Expediting the discovery of immunoregulatory | 53523
Journal of Clinical and Cellular Immunology

Journal of Clinical and Cellular Immunology
Open Access

ISSN: 2155-9899

+44 1223 790975

From bugs to drugs: Expediting the discovery of immunoregulatory bioactives from the human gut microbiota to drive the development of novel anti-inflammatory therapeutics

International Conference on Mucosal Immunology and Vaccine Development

July 28-29, 2016 Melbourne, Australia

Paraic O Cuiv

The University of Queensland, Australia

Scientific Tracks Abstracts: J Clin Cell Immunol

Abstract :

The incidences of chronic gut diseases in Australia including inflammatory bowel diseases, colorectal cancer, and obesity are amongst the highest internationally. In addition to host genetic, environmental and lifestyle factors it is now increasingly recognized that the microbial community resident in the gut (gut microbiota) has a significant influence on disease risk. Recent research has revealed that the gut microbiota of healthy individuals is characterized by a â�?�?core microbiotaâ�? of up to 125 bacterial species that are numerically abundant and widely shared amongst individuals. Furthermore, the structure of the core gut microbiota differs between the healthy and diseased gut, these differences are coincident with the onset of active disease and a restoration of key species is associated with improvements in gut health. Many core gut microbes are unrepresented by cultured isolates however several of the isolates that are available have been shown to modulate the host inflammatory response and regulate the development and/or effector functions of different immune cell populations, thus helping maintain gut homeostasis. These â�?�?bioactivesâ�? could support the development of novel therapeutics however despite a wealth of genomic and metabolomic data the vast majority of the immunomodulatory functionalities encoded by the microbiota remain cryptic. We have developed a new methodology termed â�?�?metaparental matingâ�? that enables genetically tractable core bacteria to be rapidly recovered from complex gut communities and that has the potential to transform our ability to functionally characterize gut bacteria. We anticipate that this will support the discovery of immunomodulatory bioactives and expedite the development of novel anti-inflammatory therapeutics.

Biography :

Paraic O Cuiv is Research Fellow at the University of Queensland Diamantina Institute where he has a long standing interest in the human gut microbiota and its role in the aetiology of chronic gut diseases. His expertise is primarily in microbiology, bacterial genetics and genomics and his research is currently focused on these three distinct areas.